02197.HK
Clover Biopharmaceuticals, Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 2.12
+7.36%Sep 6, 2026, 23:38 UTC
Clover Biopharmaceuticals announced positive preliminary Phase II clinical trial data for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 in 420 elderly Australians aged 60-85, showing enhanced antibody responses and reduced respiratory infection incidence.
Source:Aug 26, 2026, 01:07 UTC
Clover Biopharmaceuticals reported interim results for the six months ended June 2026, turning a profit of 955 million yuan from a loss of 101 million yuan a year earlier, mainly due to a one-time accounting gain of about 1.087 billion yuan from the GAVI settlement agreement.
Source: